Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
THRIVE: Thromboprophylaxis in Superficial Endovenous Treatment
NCT05735639Phase 4Recruiting
- Sponsor
- Imperial College London
- Start
- Jan 2024
- Primary completion
- Jun 2027
- Modality
- Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, single-blind trial of dalteparin, tinzaparin, enoxaparin, rivaroxaban, apixaban and 1 more in venous thromboembolism (VTE) (3 arms), sponsored by Imperial College London. Primary endpoint: Venous Thromboembolism at 90 days. Started Jan 2024; status: recruiting.
02
Drugs
dalteparintinzaparinenoxaparinrivaroxabanapixaban
03
Conditions
venous thromboembolism (VTE)
Beyond the preview
Go deeper on NCT05735639.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05735639.